Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

BELLUS Health to Present at the BofA Securities Virtual Health Care Conference


BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Tuesday, May 12, 2020 at the BofA Securities Virtual Health Care Conference.

Presentation Details:

Event: BofA Securities Virtual Health Care Conference
Date/Time: Tuesday, May 12, 2020 at 1:00 p.m. ET/ 10:00 a.m. PT

A live webcast may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast and presentation will be available on the Company's website.

About BELLUS Health

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.


These press releases may also interest you

at 19:30
Astellas' XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Astellas Pharma Inc....

at 19:15
New Study in Colorado Reveals Alarming Rates of Colorado Teens Missing School
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 18:00
Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plustm, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

at 17:45
BioSyent to Attend Planet MicroCap Showcase
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...

at 17:44
Honoring Audrey Beverly Christy Mastroianni at United Breast Cancer Foundation's Mattress and Pink Bag Event: "Gifts of Comfort and Hope" in Warwick, Rhode Island
United Breast Cancer Foundation (UBCF) is proud to host a heartfelt event dedicated to honor the memory of Audrey Beverly Christy Mastroianni, a remarkable Rhode Island woman who bravely battled breast cancer. The "Gifts of Comfort and Hope" Mattress...

More news about Health...


News published on and distributed by: